Trials / Terminated
TerminatedNCT04427774
A Study of Surufatinib Plus Sintilimab in Patients With Advanced Solid Tumor
A Phase Ib Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of Surufatinib Plus Sintilimab in Patients With Advanced Solid Tumor
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 8 (actual)
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety and efficacy of Surufatinib plus Sintilimab in Patients with Advanced Solid Tumor
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Surufatinib plus Sintilimab | Surufatinib will be given orally. Sintilimab will be given intravenously |
Timeline
- Start date
- 2020-06-29
- Primary completion
- 2021-02-08
- Completion
- 2021-04-27
- First posted
- 2020-06-11
- Last updated
- 2021-07-20
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04427774. Inclusion in this directory is not an endorsement.